Bluebird Bio, a Cambridge, Mass.-based biotechnology company, is proposing a new strategy to pay for the expected seven-figure price of its new experimental gene therapy — installments, according to The Wall Street Journal.
Pharmacy
Takeda finalized its $62 billion acquisition of Shire Jan. 8, catapulting the Japanese company into a new league of pharma giants, according to Bloomberg.
The FDA plans to establish the Office of Drug Evaluation Science to improve and modernize the review process for new medications, according to STAT.
The U.S. Supreme Court seems unlikely to reject a common legal strategy drugmakers use to defend themselves against patient lawsuits, according to STAT.
CVS Pharmacy is buying Ritzman Pharmacy, a 20-store retail pharmacy chain with locations in northeast Ohio.
Advertisement
Celgene, on the same day it announced it would be acquired by Bristol-Myers Squibb, raised the price of its top cancer treatment Revlimid by 3.5 percent, according to Bloomberg.
Price hikes on existing drugs and new medications coming to market are the primary contributors to rising prescription drug prices, a new study published in Health Affairs reveals.
Eli Lilly plans to acquire Loxo Oncology for $8 billion in cash to expand its portfolio of cancer medications, according to CNBC.
As debate continues over U.S. drug prices, pharmaceutical companies may need to increasingly show greater efficiencies and research and development productivity in 2019, according to Fitch Ratings.
Twelve additional health systems have joined Civica Rx, a nonprofit company formed by hospitals to manufacture their own generic medicines.